Regeneron Pharmaceuticals will repurchase about $5 billion of the U.S. drugmaker’s shares directly from France’s Sanofi, without altering their 17-year partnership.

The Sumitomo Dainippon-Roivant Alliance encompasses up to 11 biopharmaceutical Vants with more than 25 innovative clinical programs and multiple potential product launches from 2020 to 2022, and access to key elements of Roivant’s proprietary technology platforms including DrugOme and Digital Innovation.